FibroGen Inc. (FGEN), a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer, has significant catalysts to watch in the upcoming months.
The company's lead drug candidate is Pamrevlumab, which is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer.
A phase II/III adaptive platform trial, which is evaluating Pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma, dubbed Precision Promise, is underway. Topline data from this registration study is anticipated in the second quarter of 2024.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.